Metformin Accord (Metformin Hydrochloride)

Metformin primarily inhibits mitochondrial complex I, which reduces hepatic gluconeogenesis. It also enhances insulin‑mediated glucose uptake in muscle and fat tissues by promoting GLUT4 translocation, leading to lower circulating glucose levels and modest weight loss.

The specific dose of Metformin Accord is determined by the prescribing healthcare professional based on the individual’s clinical condition, renal function, and response to therapy. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Metformin may be used during pregnancy or lactation only when the potential benefit justifies the potential risk to the fetus or infant. Healthcare providers evaluate each case individually, and patients should discuss any concerns with their prescriber.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Metformin belongs to the biguanide class and is often first‑line therapy because of its efficacy, low risk of hypoglycaemia and favourable impact on weight. Compared with sulfonylureas, it does not stimulate insulin release, and unlike insulin, it is taken orally and does not cause weight gain.

Metformin Accord should be stored at ambient temperature, below 25 °C, in its original packaging. Keep the product away from moisture, heat and direct sunlight to maintain its stability and potency.

Metformin Accord is taken orally, usually with meals to reduce gastrointestinal discomfort. The tablet should be swallowed whole with a glass of water; it is not intended for crushing, chewing, or dissolving unless specifically instructed by a healthcare professional.

The most serious risk is lactic acidosis, a rare but potentially fatal condition that can occur in patients with severe renal or hepatic impairment, excessive alcohol intake, or acute illness. Prompt medical attention is required if symptoms such as rapid breathing, muscle pain, or abdominal discomfort develop.

Metformin Accord is contraindicated in patients with severe renal impairment (eGFR <30 mL/min/1.73 m²), known hypersensitivity to metformin, acute or chronic metabolic acidosis, and in those receiving iodinated contrast studies without appropriate renal monitoring.